Assessing the impact of WTC dust exposure on prostate cancer recurrence
Project Number5U01OH012628-02
Contact PI/Project LeaderAARONSON, STUART A Other PIs
Awardee OrganizationICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Description
Abstract Text
PROJECT SUMMARY
This application addresses targeted health issues through a Cooperative Research Agreement with the World
Trade Center (WTC) Health Program (UO1). The presence of carcinogens and inducers of inflammation in WTC
dust have raised the possibility that those exposed to WTC dust during the 9/11 attacks could have increased
cancer incidence. To date, several cohort studies indicate that total cancer rates are 6-14% above background
rates with significantly greater increases for thyroid and prostate cancer (Moir, 2016; Solan, 2013; Li, 2012;
Jordan, 2011; Zeig-Owens, 2011).
Increased exposure based on the time of arrival for workers, their proximity to early response to the WTC and
duration of exposure have been associated with increased risk of tumor progression (de la Hoz, 2008; Lioy and
Georgopoulos, 2006). Recent studies in small animal models indicate that WTC dust particles or metals are
undetectable or present at exceedingly low levels in prostate tissues compared to lung following WTC dust
exposure by inhalation or gavage (Wang, 2022; Gong, 2019), and long-term studies of rodents have not revealed
evidence of a direct carcinogenic mechanism. Instead, there is evidence from both human RNA expression and
DNA methylation analyses (Yu, 2022) and animal models (Wang, 2022; Gong, 2019) that inflammation induced
by this dust may be implicated in promoting prostate cancer. In the mouse, WTC dust exposure promotes
systemic as well as localized prostate inflammation, increased growth in PTEN deficient prostate epithelia and
promotion of genetically initiated prostate tumors (Wang, 2022).
Aim 1 will investigate whether WTC associated prostate cancer is more likely to recur independent of tumor
grade at diagnosis and if there are molecular signatures of aggressiveness at diagnosis in those who recur. We
will utilize increased biochemical (PSA) recurrence to define responders with adverse clinical response to WTC
dust following surgery or radiation therapy. We will also apply recently identified signatures by RNA expression
analysis and mass spec multiplex immunostaining of primary prostate cancer tissues to test whether these
immune/inflammatory markers correlate with increased tumor recurrence in WTC responders.
Aim 2 will focus on correlating our human findings with those in mouse genetically engineered mouse models
bearing targeted lesions to prostate that model human PC. These experiments take advantage of our strong
preliminary evidence that these models support a role of WTC dust exposure in PC progression. Experiments
will include testing whether WTC dust exposure promotes recurrence of genetically initiated PCs following
androgen deprivation therapy and/or experimental PC metastasis. We will also compare, and contrast WTC dust
associated immune/inflammatory biomarkers in the mouse with those identified in human PCs.
Our overarching goal is to translate understanding gained toward improved surveillance of WTC responders
most at risk for prostate cancer.
Public Health Relevance Statement
Project Narrative. This project will investigate how exposure to World Trade Center (WTC) dust during the 9/11
attacks impacts prostate cancer recurrence in First Responders with correlative mechanistic studies in relevant
mouse genetic models. The results should aid in assessing whether responders with high exposure levels
require increased active surveillance for evidence of biochemical recurrence and the presence of more
aggressive disease.
National Institute for Occupational Safety and Health
CFDA Code
262
DUNS Number
078861598
UEI
C8H9CNG1VBD9
Project Start Date
01-July-2023
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$499,998
Direct Costs
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
National Institute for Occupational Safety and Health
$499,998
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U01OH012628-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01OH012628-02
Patents
No Patents information available for 5U01OH012628-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01OH012628-02
Clinical Studies
No Clinical Studies information available for 5U01OH012628-02
News and More
Related News Releases
No news release information available for 5U01OH012628-02
History
No Historical information available for 5U01OH012628-02
Similar Projects
No Similar Projects information available for 5U01OH012628-02